Swedish Orphan Biovitrum Returns Long-Acting Blood Clotting Factors To Biogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec gains sole development and manufacturing rights to long-acting Factor VIII and Factor IX products previously in joint development with Swedish Orphan Biovitrum.
You may also be interested in...
Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal
Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.